Stay in touch
We'd love to keep in touch about news, events and how you can get involved. To hear from us, please sign up below.
We answer some common questions about the current COVID-19 vaccines and breast cancer treatments.
I look after the Moving Forward gallery on our website as one part of my work here in the Marketing team.
The gallery's open to anyone moving on from hospital-based treatment for breast cancer to share their experiences and a photo.
We’re delighted to announce that Vita – Breast Cancer Care’s popular quarterly magazine – has a brand new website.
So that people using our information know we understand their situation it’s important to us that the images we use show real women affected by breast cancer, such as Jenny pictured here.
A new system of pricing branded medicines known as value-based pricing (VBP) is due to start from January 2014. The aim is to give NHS patients better access to effective and innovative medicines.
However there's still time for us to highlight the particular needs and issues of people affected by breast cancer as the Department of Health (DH) and The Association of the British Pharmaceutical Industry (ABPI) continue to discuss how VBP will work.
Today the All-Party Parliamentary Group on Breast Cancer (APPGBC) launches its report Age is just a number. It makes recommendations about tackling the issues surrounding inequality in treatment services and support available to older people with breast cancer.
As our Policy and Campaigns team presented our research campaigns and services work to the All Party Parliamentary Group on Breast Cancer last month other Breast Cancer Care staff were at a conference for healthcare professionals and patient groups.
Five pence from every pack sold of Smint's new fruity and refreshing strawberry flavour is coming to us from Smint’s parent company Perfetti Van Melle.
Arena Racing Company (ARC) is supporting us with an exciting series of Ladies Days and Ladies Evenings race meetings this summer.
The National Institute for Health and Care Excellence (NICE) has recommended that a drug called everolimus (Afinitor) should not be used by the NHS to treat a specific type of secondary breast cancer.